As the pharmaceutical industry embraces digital transformation, new technologies have the potential to sink or swim. How can the industry ensure it’s backing the most effective innovations and not getting stuck in dead ends?

The COVID-19 pandemic has reshaped pharmaceutical sales, moving from face-to-face to predominantly digital interactions. How can sales reps adapt to multichannel approaches and enhance performance amidst this shift in sales training and team dynamics?

The pharmaceutical industry’s digital transformation during the pandemic has fuelled fresh opportunities to collect and harness data, but this venture must be approached with a strong consideration for consent and preference management rules

An interview with Tamika-Jean Baptiste, Vice President and Chief Diversity Officer, Amgen.

Rejection is always painful, but it is particularly agonising to have a drug rejected at the point of regulatory approval. After spending months researching, preparing, manufacturing and quality checking a drug, only to be sent back to the drawing board, how can companies get back into their creationary swing straight away?

The corporate environment is evolving, and ‘purpose’ is more important than ever to young recruits looking for their next role. We examine how the pharmaceutical industry is embracing the importance of purpose for retention, reputation, and brand differentiation

From drug development to disposal, how can all processes and functions be considered through a greener lens, and work towards a healthier and safer future?

While the potential of cell and gene therapies (CGTs) is huge, the high cost raises concerns from payers. We explore how the industry can drive the adoption of CGTs to ensure that they reach patients around the world, rather than just those in private markets